Key Highlights
- Fiscal fourth-quarter Revenue was about $1.46 billion, up about 9%, with full-year fiscal 2026 revenue of about $5.7 billion, up about 10%.
- Non-GAAP gross Margin expanded about 90 basis points to about 62.3%, and non-GAAP EPS was about $2.95, up about 16%, beating estimates.
- A field-safety action on its Astral ventilators prompted a roughly $42 million provision and an expected roughly $75 million revenue impact in fiscal 2027.
- ResMed divested its MatrixCare software Business for about $490 million and raised its Dividend about 10% to about $0.66.
ResMed (NYSE:RMD) fell 3.64% to $231.36 at last closing. The leader in sleep-apnea and respiratory-care devices delivered strong revenue and Earnings growth with expanding margins in its fiscal fourth quarter, even as a safety action on its Astral ventilators created a headwind. For investors, the question is whether the company's core growth and margin strength can outweigh the Astral issue.
ResMed makes devices and software for sleep apnea and respiratory care, including CPAP devices, masks and ventilators, along with residential-care software. Its results depend on sales of its sleep and breathing devices and its gross margins.
Latest Developments
In its fiscal fourth-quarter 2026 results, ResMed reported revenue of about $1.46 billion, up about 9%, with full-year fiscal 2026 revenue of about $5.7 billion, up about 10%. Non-GAAP gross margin expanded about 90 basis points to about 62.3%, and non-GAAP EPS was about $2.95, up about 16%, beating estimates. However, a field-safety action on its Astral ventilators created a headwind, prompting a roughly $42 million provision and an expected roughly $75 million revenue impact in fiscal 2027. ResMed divested its MatrixCare software business for about $490 million and raised its dividend about 10% to about $0.66.
Financial and Business Position
ResMed's strong revenue and earnings growth and its expanding margins reflect the strength of its leading sleep-apnea and respiratory-care franchise. The Astral ventilator safety action is a near-term headwind with a provision and a fiscal-2027 revenue impact. The considerations for investors include competition and the pace of new-patient diagnosis.
Stock-Market Context
ResMed (NYSE:RMD) fell 3.64% at last closing, a decline that reflects the Astral headwind despite otherwise strong results. The improvement case rests on continued strong device and mask growth and margin expansion, alongside the Astral issue being managed; the cautionary case is the Astral headwind and competitive and GLP-1-related debates.
What Investors Should Watch
Investors may focus on sleep-device and mask revenue growth, gross margins, and the Astral ventilator situation and its resolution. Evidence that ResMed can sustain its core device and mask growth while managing the Astral headwind would do the most to support the shares.






Please wait processing your request...